Alaska Permanent Fund Corp Has $1.91 Million Holdings in Organon & Co. (NYSE:OGN)

Alaska Permanent Fund Corp grew its stake in shares of Organon & Co. (NYSE:OGN) by 12.3% during the fourth quarter, according to the company in its most recent disclosure with the SEC. The fund owned 132,078 shares of the company’s stock after buying an additional 14,478 shares during the quarter. Alaska Permanent Fund Corp’s holdings in Organon & Co. were worth $1,905,000 as of its most recent SEC filing.

A number of other large investors also recently modified their holdings of OGN. Fruth Investment Management increased its stake in shares of Organon & Co. by 1.9% in the fourth quarter. Fruth Investment Management now owns 37,040 shares of the company’s stock valued at $534,000 after buying an additional 700 shares during the period. Daiwa Securities Group Inc. increased its holdings in Organon & Co. by 15.9% in the third quarter. Daiwa Securities Group Inc. now owns 6,032 shares of the company’s stock valued at $105,000 after purchasing an additional 828 shares during the period. New Mexico Educational Retirement Board raised its position in Organon & Co. by 7.3% during the 3rd quarter. New Mexico Educational Retirement Board now owns 13,268 shares of the company’s stock worth $230,000 after purchasing an additional 900 shares during the last quarter. Mackenzie Financial Corp lifted its holdings in Organon & Co. by 7.6% during the 3rd quarter. Mackenzie Financial Corp now owns 13,148 shares of the company’s stock worth $214,000 after buying an additional 932 shares during the period. Finally, Beddow Capital Management Inc. raised its position in shares of Organon & Co. by 1.8% during the third quarter. Beddow Capital Management Inc. now owns 52,879 shares of the company’s stock worth $918,000 after acquiring an additional 946 shares during the last quarter. 77.43% of the stock is currently owned by institutional investors.

Organon & Co. Price Performance

Shares of Organon & Co. stock opened at $18.50 on Friday. The stock’s 50-day moving average is $18.14 and its 200 day moving average is $15.69. Organon & Co. has a one year low of $10.84 and a one year high of $24.79. The firm has a market cap of $4.73 billion, a price-to-earnings ratio of 4.61, a PEG ratio of 0.89 and a beta of 0.83.

Organon & Co. (NYSE:OGN) last posted its quarterly earnings results on Thursday, February 15th. The company reported $0.87 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $0.73 by $0.14. The firm had revenue of $1.60 billion for the quarter, compared to analysts’ expectations of $1.55 billion. Organon & Co. had a negative return on equity of 212.00% and a net margin of 16.33%. On average, sell-side analysts expect that Organon & Co. will post 4.08 EPS for the current fiscal year.

Organon & Co. Dividend Announcement

The business also recently announced a quarterly dividend, which was paid on Thursday, March 14th. Investors of record on Monday, February 26th were paid a dividend of $0.28 per share. This represents a $1.12 annualized dividend and a yield of 6.05%. The ex-dividend date was Friday, February 23rd. Organon & Co.’s dividend payout ratio is presently 28.00%.

Insiders Place Their Bets

In related news, insider Kirke Weaver acquired 2,720 shares of the company’s stock in a transaction dated Thursday, February 22nd. The shares were purchased at an average price of $18.36 per share, for a total transaction of $49,939.20. Following the completion of the acquisition, the insider now owns 15,181 shares of the company’s stock, valued at $278,723.16. The acquisition was disclosed in a filing with the SEC, which is available through the SEC website. Corporate insiders own 1.17% of the company’s stock.

Wall Street Analyst Weigh In

Separately, The Goldman Sachs Group raised their price target on shares of Organon & Co. from $16.00 to $18.00 and gave the stock a “neutral” rating in a report on Tuesday, February 20th.

About Organon & Co.

Organon & Co develops and delivers health solutions through a portfolio of prescription therapies and medical devices within women's health in the United States and internationally. Its women's health portfolio comprises contraception and fertility brands, such as Nexplanon, a long-acting reversible contraceptive; NuvaRing, a monthly vaginal contraceptive ring; Cerazette, a daily pill used to prevent pregnancy; Marvelon, progestin and estrogen used as daily pills to prevent pregnancy; Follistim AQ, used to promote the development of multiple ovarian follicles in assisted reproduction technology procedures; Elonva, an ovarian follicle stimulant; Ganirelix Acetate Injection, an injectable antagonist; and Jada, for abnormal postpartum uterine bleeding or hemorrhage.